Featured Research

from universities, journals, and other organizations

'Heart resilience' biomarker may help predict chemotherapy-induced cardiac damage earlier

Date:
December 21, 2012
Source:
Ohio State University Center for Clinical and Translational Science
Summary:
Anthracyclines, a class of chemotherapy drugs commonly used to treat breast and childhood cancers are effective, but can cause heart damage that doesn't appear until long after treatment is over. By analyzing cardiac magnetic resonance imaging and heart health biomarkers in breast cancer patients, researchers were able to identify slight changes in heart function that could help identify which cancer patients are more likely to suffer cardiac issues later in life.

By using a blend of high definition cardiac imaging and biomarkers, Ohio State University cancer and heart researchers think they may have a way to catch early heart damage caused by anthracyclines, a class of chemotherapy drugs commonly used to treat breast and childhood cancers.

Presented at the recent San Antonio Breast Cancer Symposium, and funded by the Ohio State Center for Clinical and Translational Science (CCTS), the study looked at breast cancer patients being treated with doxorubicin, a type of anthracycline that is effective at treating breast cancer, but may lead to future heart problems in some women long after the treatment is complete.

"Currently, we are unable to predict who is more likely to develop heart problems, and we usually only catch the damage once it's too late." said Dr. Maryam Lustberg, a breast oncologist at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James). "If we could identify these at-risk patients earlier, we could introduce cardio-protective drugs or eliminate cardio-toxic drugs."

The study honed in on measuring epithelial progenitor cells (EPCs) -- a rare cell type found in the bloodstream that can indicate cardiac reserve, a measure of how resilient the heart can be in recovering from various insults. EPC levels are a well-established predictor of outcomes in patients with heart attacks or heart disease, but the researchers are the first to explore their use in predicting which chemotherapy patients may be at highest risk for developing cardiac injury after exposure to anthrcyclines.

In addition to looking at EPCs, researchers analyzed heart function and physical changes to the heart using cardiac magnetic resonance imaging (CMR), as well as measuring blood levels of troponin and BNP, two biomarkers that indicate cardiac damage. Measurements were taken before, during and after the course of treatment, which for breast cancer patients, typically lasts about two months.

Researchers found that patients who came in with lower EPCs were more likely to have higher levels of troponin in their blood by the end of treatment. While the treatment was well-tolerated, and there were no acute indications of damage to heart function, the researchers also identified a trend in physical changes in the heart, including increased water content in heart cells and indications that the heart was working less efficiently.

Dr. Subha Raman a cardiologist and professor of cardiovascular medicine at Ohio State's Wexner Medical Center noted, "By pairing CMR with measuring the amount of chemical messengers in the blood stream, we're building a solid foundation that may help us develop a predictive model in the future."

The researchers plan to reassess patients at 12 and 24 months, and hope to follow the study group for as long as five years in order to capture more data.

"This kind of research is a testament to the fact that survival rates after a cancer diagnosis have never been higher. We want to make sure that life after cancer treatment is as healthy as possible," said Lustberg.


Story Source:

The above story is based on materials provided by Ohio State University Center for Clinical and Translational Science. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University Center for Clinical and Translational Science. "'Heart resilience' biomarker may help predict chemotherapy-induced cardiac damage earlier." ScienceDaily. ScienceDaily, 21 December 2012. <www.sciencedaily.com/releases/2012/12/121221081432.htm>.
Ohio State University Center for Clinical and Translational Science. (2012, December 21). 'Heart resilience' biomarker may help predict chemotherapy-induced cardiac damage earlier. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/12/121221081432.htm
Ohio State University Center for Clinical and Translational Science. "'Heart resilience' biomarker may help predict chemotherapy-induced cardiac damage earlier." ScienceDaily. www.sciencedaily.com/releases/2012/12/121221081432.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins